| Company Name | AstraZeneca Taiwan Ltd |
|---|---|
| Protocol Number | D1690R00044 |
| Title of Study | iCaReMe Global Registry Real-world Multinational Registry to Determine Management and Quality of Care of Patients With Type 2 Diabetes, Hypertension, Heart Failure and/or Chronic Kidney Diseases |
| Primary Objective | Aims to describe the real-world patient characteristics, treatment patterns in cardiovascular and renal disease, HTN, and T2D |
| Number of Sites | 12 |
| Period of Study | From：Oct/2023 to：Jun/2026 |
| Number of Patients | 1200人 |
| IRB Approval Date | 中山附醫: Jan/26/2024 成大醫院: Dec/22/2023 高雄長庚: Jan/15/2024 林口長庚: Jan/15/2024 中國附醫: Jan/26/2024 彰化基督教醫院: Mar/6/2024 台中榮總: Apr/26/2024 國泰醫院: Jul/26/2024 童綜合醫院: Jun/5/2024 馬偕醫院: Aug/6/2024 臺大醫院: Jul/31/2024 三軍總醫院: N/A |
| Publication Plan / Date | Unknown/未知 |
